Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patientsLONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American Diabetes Association 83rd Scientific Sessions (June 23-26, 2023) in San Diego, California and another abs
Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Dr George Bakris elaborates on the risk factors, monitoring, treatment objectives, and the impact of diet and exercise in preventing the progression of diabetic kidney disease.
Drs Diana Isaacs and Natalie Bellini emphasize the need for early detection of diabetic kidney disease through the monitoring of cardiometabolic risk factors.